Abstract
The estimates on cancer incidence, late diagnosis and mortality rates currently and for 2030 are disappointing, suggesting a remarkably limitations of current conventional research to manage and control this complex disease [1, 2]. To overcome these pessimistic figures the transition from current inexact biomedical research to whole genome, transcriptome and interactome analysis with sequencing, editing and interaction network mapping appear essential [3-7]. Latest achievements in understanding tumorigenesis, dynamic cancer genome evolution and progress to early tumor formation is essential for the development of clinical primary prevention [[8].
Moreover, the development of novel screening tools via liquid biopsy-based cfDNA-NGS is described [9]. Furthermore, the optimization of individualized therapy through the creation of a Drug bank coupled with predictive biomarkers are also highlighted [10].
.
(Citation: Gastric & Breast Cancer 2021; 16(1): 56-63)
|
